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Introduction
Two of the most common malignancies of the female genital
tract are endometrial and cervical cancer. They are separate
entities with different epidemiology, pathogenesis, and histol-
ogy, but are linked by their origin in the uterus. Although they
have garnered less attention in developed countries than ovari-
an carcinoma, it is important to recognize that endometrial car-
cinoma is the most common female genital tract malignancy in
the United States, and that cervical carcinoma is the second
most common cancer in women worldwide. Thus, these are
highly prevalent cancers, and their further study has the poten-
tial for significant beneficial impact on women’s health on an
international level.
(1) Endometrial cancer
Epidemiology and incidence statistics
Malignancies that arise in the endometrium are collectively
referred to as endometrial cancer. However, the term is often
used synonymously with endometrial carcinoma, as it accounts
for more than 95% of endometrial cancers. Although the data on
incidence and outcome refer to endometrial cancer, due to the
preponderance of endometrial carcinoma, the numbers largely
reflect its incidence and outcome. In the United States, endome-
trial cancer is the eighth most common cause of cancer deaths
and the fourth most common cancer in women. It is also the
most common malignancy of the female genital tract. The
American Cancer Society predicts that 40,320 women will be
diagnosed with endometrial cancer in 2004 and that 7,090 will
die of the disease. What is not evident from these data is the
large number of hysterectomies performed to treat the noninva-
sive precursors of endometrial carcinoma, which contribute sig-
nificantly to the morbidity related to endometrial neoplasia.
Overall, endometrial cancer has an 86% five-year survival rate.
This almost certainly reflects the fact that the disease usually
comes to the attention of women early because of abnormal
vaginal bleeding, and they are treated with a hysterectomy
before the disease has spread beyond the uterus. Unfortunately,
if it has extended outside the uterus, neither radiation nor
chemotherapy significantly increases long-term survival.
Clinicopathologic characteristics and therapeutics
The endometrium is a complex tissue that lines the uterine cav-
ity and is composed of both glandular and stromal elements.
The cyclic proliferation, differentiation, and sloughing of both
components is exquisitely controlled and coordinated by steroid
hormones produced by the ovary. In general, estrogen pro-
motes the proliferation and progesterone the differentiaton of
both components. Endometrial carcinoma arises from the
epithelial component and has historically been thought of as a
single disease. However, in 1983, a clinicopathological study
suggested that endometrial carcinoma could be broadly divided
into two major types, referred to as type I and type II (Bokhman,
1983).These findings have now, for the most part, been accept-
ed and have provided a logical paradigm for studying endome-
trial carcinoma (Figure 1).
Type I carcinomas are associated with a constellation of
clinical findings (obesity, hypertension, diabetes) and a hypere-
strogenic state.The tumors are in general low-grade (i.e., well to
moderately differentiated), low-stage (confined to the uterus),
indolent tumors often associated with endometrial hyperplasia.
If left untreated, endometrial hyperplasia, a proliferative process
of the endometrial glands, can progress to carcinoma (Kurman
et al., 1985). Moreover, Type I tumors are of endometrioid histol-
ogy, that is, they resemble normal proliferative endometrial
glands. These tumors are usually treated with surgery with or
without radiation depending on the stage of the tumor. If the
tumors are metastatic, adjuvant chemotherapy is used, but this
results in little, if any, improvement in survival.
Type II tumors are found in the setting of atrophy and are not
associated with unopposed estrogen.They are poorly differenti-
ated tumors and behave in an aggressive manner. The most
common histologic tumor type associated with type II tumors is
serous carcinoma; however, poorly differentiated endometrioid
and clear cell tumors are generally placed in this category.
Serous carcinoma is composed of markedly atypical cells that
can grow in papillary, glandular, or solid patterns. The precursor
of serous carcinoma, endometrial intraepithelial carcinoma
(serous EIC), consists of cells resembling those of serous carci-
noma that line the surface of atrophic endometrium but do not
invade the underlying stroma. The aggressive nature of this
neoplastic process is highlighted by the fact that serous EIC,
even in the absence of a detectable invasive component, often
presents with associated peritoneal metastases. Since the
recognition of the similarities between this tumor type and ovar-
ian carcinoma (e.g., early peritoneal spread, p53 mutations,
etc.), it is most commonly treated with chemotherapeutic regi-
mens used for ovarian cancer.
Molecular pathogenesis
Endometrioid carcinoma. Endometrioid carcinoma accounts for
approximately 80% of all cases of endometrial cancer and is
divided into three grades based on histologic criteria. Grades 1
(well differentiated) and 2 (moderately differentiated) are the
most common and fall into the Type I category, whereas Grade
3 tumors are often thought of as Type II tumors because they
portend a poor prognosis.
The PTEN tumor suppressor gene is the most frequently
altered gene in this tumor type, with mutations present in approx-
imately 50% of tumors (Tashiro et al., 1997a). In addition, muta-
tions have been detected in approximately 20% of hyperplastic
lesions, suggesting that mutations in PTEN occur relatively early
in the pathogenesis of endometrioid carcinoma (Levine et al.,
1998; Maxwell et al., 1998). There is a wide spectrum of muta-
tions of PTEN in endometrioid carcinoma, which primarily occur
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in exons 3, 4, 5, 7, and 8, targeting the phosphatase domain and
regions that control protein stability and localization. Many of the
mutations result in decreased or absent expression of PTEN,
documented by both Western blot analysis and immunohisto-
chemistry. One study has found loss of PTEN expression in clus-
ters of morphologically benign glands, suggesting that PTEN
mutation may precede the development of detectable light
microscopic lesions (Mutter et al., 2000). Other data have sug-
gested that epigenetic mechanisms (e.g., promoter hypermethy-
lation) and subcellular localization can affect PTEN function in
the absence of intragenic mutations.
Microsatellite instability (MI) was first detected in tumors aris-
ing in individuals with hereditary nonpolposis colorectal cancer
(HNPCC). Since endometrial carcinoma is the second most com-
mon tumor in women with HNPCC, MI studies were performed,
and MI was detected in approximately 25% of sporadic endome-
trial cancers (Gurin et al., 1999). Unlike the familial cases in which
the affected member carries a germline mutation in one of the
DNA mismatch repair genes, hMLH1 promoter hypermethylation
is the predominant cause of MI in sporadic cases. MI can be
found in complex atypical hyperplasia associated with invasive
cancer, but it has not been found in lesser degrees of hyperplasia
(Levine et al., 1998). However, promoter hypermethylation of
hMLH1 has been detected in hyperplasia lacking an associated
carcinoma, suggesting that inactivation of mismatch repair pre-
cedes the development of MI (Esteller et al., 1998). Although it
remains unclear exactly when in the development of endometrial
neoplasia the DNA mismatch repair system becomes inactivated,
these findings suggest that it may occur early in its pathogenesis.
Several studies have reported a statistically significant associa-
tion between PTEN mutations and MI. The mechanism(s) under-
lying the association is uncertain, but recent data suggest that it
has biological significance.The exact mechanisms by which DNA
mismatch repair inactivation contributes to the development of
endometrioid carcinoma remain largely unknown, but PTEN may
represent one possible target. Answers to this question are not
only of biological interest, but may also have important clinical
ramifications in predicting which lesions are at risk of progression
and require future focused investigation.
The p53 tumor suppressor gene has received considerable
attention in endometrial cancer, as it has in most tumor types,
and along with other genetic alterations has provided important
pathogenetic information for distinction between the two types
of endometrial carcinoma. Mutations in p53 are found in approx-
imately 10%–20% of all endometrioid carcinomas, the majority
occurring in high-grade tumors (Lax et al., 2000). Approximately
50% of Grade 3 tumors, and rare Grade 2 tumors, contain p53
mutations, but they have not been identified in Grade 1 tumors
or endometrial hyperplasia.
The most commonly altered oncogene in endometrial carci-
noma is K-ras, which is mutated in 10%–30% of cases. The
mutations have been found in all grades of endometrioid carci-
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Figure 1. Histological and molecular characteristics of endometrial lesions
The precursor lesions are shown on the left and the invasive tumors on the right. The common molecular genetic alterations found in each morphologic enti-
ty are shown directly below each photomicograph. SH, simple hyperplasia; CH, complex hyperplasia; CAH, complex atypical hyperplasia; G1, Grade 1
endometrioid carcinoma; G2, Grade 2 endometrioid carcinoma; G3, Grade 3 endometrioid carcinoma; EIC, endometrial intraepithelial carcinoma; USC,
papillary form of serous carcinoma; USC glandular, glandular form of serous carcinoma.
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noma and have been reported in complex atypical hyperplasia,
suggesting a relatively early role for K-ras mutations in this
tumor type. Most recently, mutations in the CTNNB1 (β catenin)
gene have been found in approximately 13% of endometrioid
carcinomas, with an accumulation of the protein found in 38% of
cases (Fukuchi et al., 1998). This genetic abnormality is closely
associated with squamous metaplasia, and a recent article
found an associated increase in p53 and cyclin D1 expression
in the areas of metaplasia (Saegusa et al., 2004).
Molecular data now exist which suggest that most Grade 2,
and at least some Grade 3, tumors have molecular profiles sim-
ilar to Grade 1 tumors (e.g., PTEN and K-ras mutations, and
MSI). These findings suggest that although Grade 3 tumors
have a poor prognosis, like Type II tumors, they can share a sim-
ilar genetic profile to Grade 1 and 2 tumors.
Serous carcinoma. Serous carcinoma, the prototype of Type II,
accounts for only 10%–15% of all endometrial carcinomas.
Although a number of cancer-causing genes have been stud-
ied, only the p53 tumor suppressor gene is consistently altered
in a significant number of cases. Some studies have detected
p53 mutations in almost 90% of serous carcinomas (Tashiro et
al., 1997b). The same study found that approximately 75% of
endometrial intraepithelial carcinomas, the putative precursor of
serous carcinoma, also have mutations in p53, implicating a
role for its inactivation early in the development of this aggres-
sive tumor type.This is in contrast to endometrioid carcinoma in
which p53 mutations are relatively uncommon and are largely
confined to Grade 3 tumors. The early inactivation of p53 in the
pathogenesis of serous carcinoma may be a factor in its aggres-
sive behavior. In addition, the fact that p53 mutations occur
most commonly in Grade 3 endometrioid and serous carcino-
mas may explain why overexpression and mutation of p53 has
been found to be an independent indicator of poor prognosis in
several multivariable analyses. In cases in which the morpholo-
gy is not certain, immunohistochemical stains for p53 can be
used to make the distinction between endometrioid and serous
carcinoma, a distinction that has true clinical consequences.
In contrast to endometrioid carcinoma, mutations in K-ras
and PTEN are rare in serous carcinoma. Additionally,
microsatellite instability is extremely uncommon. Scattered
studies have found amplification and overexpression of c-myc
and Her-2/neu; however, it is not clear from the literature what
percentage of serous carcinoma demonstrate these alterations.
The molecular studies of endometrial carcinoma, like with
other epithelial-derived tumors, support their development from
preinvasive lesions via the accumulation of genetic alterations
providing the cell with the attributes necessary for unregulated
growth. In endometrioid carcinoma, PTEN alterations and
microsatellite instability occur early and set the stage for the
acquisition for mutations in other cancer-causing genes (e.g., K-
ras, p53, CTNNB1, etc.) in the progression to malignancy.
Conversely, p53 mutations appear to be critical in the conver-
sion of relatively quiescent, atrophic endometrium to an intraep-
ithelial form of serous carcinoma that then leads to alterations in
yet unidentified cancer-causing genes. Finally, although the
dualistic model is valid, it may not adequately encompass the
more uncommon types of endometrial carcinoma. Future stud-
ies will hopefully increase our understanding of the pathogene-
sis of endometrial carcinoma and refine the current broad
classification system.
Animal models
As described above, several studies have shown that MI and
mutations in PTEN are restricted, with rare exceptions, to the
estrogen-related endometrioid subtype of endometrial cancer.
Furthermore, an association between MI and PTEN mutations,
the most common alterations in endometrioid carcinoma, has
been identified, but the nature of the association remains
unclear.
Several models have recently been developed using trans-
genic approaches to regulate the expression of Pten and Mlh1.
These mice develop both hyperplastic as well as invasive carci-
noma that closely resemble the human disease. Furthermore,
Pten+/− mice lacking a functional DNA mismatch repair system
(Pten+/−/Mlh−/−) have an accelerated onset of hyperplasia and
carcinoma (Wang et al., 2002). This model may provide mecha-
nistic insights into the association between the two most com-
mon alterations in endometrioid carcinoma. An analysis of the
neoplastic lesions arising in both Pten+/− and Pten+/−/Mlh−/− mice
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Figure 2. HPV-infected malignant cells displaying upregulated p16INK4A
Staining was performed on consecutive sections. 
A: H&E stain of a lesion biopsied from a patient with squamous cell carci-
noma of the cervix. The biopsy shows an area of malignant tumor cells sep-
arated from benign squamous epithelium by a region of normal stromal
tissue. The tumor cells show abnormal squamous differentiation. 
B: Immunohistochemical stain for p16INK4A. p16-positive areas stained brown
within the tumor. 
C: HPV in situ hybridization. Presence of HPV-16 genomes was indicated by
a brown, speckled pattern within the nuclei of tumor cells.
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shows that the lesions (hyperplasias and carcinomas) demon-
strated decreased expression of Pten by immunohistochem-
istry. Furthermore, in every lesion detected by light microscopic
evaluation, irrespective of size or architecture, phosphorylated
Akt was detected by immunohistochemical analysis. Although
other downstream targets in the Pten pathway may play a role in
the development/progression of endometrial tumorigenesis,
these studies indicate a central role for phosphorylated Akt.
(2) Cervical cancer
Epidemiology and incidence statistics
Worldwide, cervical cancer is the second most common malig-
nancy among women, with nearly 80% of cases arising in less
developed countries. There are approximately 500,000 diag-
noses of cervical cancer per year worldwide, leading to approx-
imately 200,000 deaths each year. Based on the 2002
estimates of the American Cancer Society, approximately
13,000 cases of cervical cancer were diagnosed in the United
States, and approximately 4,100 women will die as a result
(Jemal et al., 2002). The primary factor in the development of
cervical cancer is infection by the human papillomavirus (HPV).
Approximately 90% to 98% of cervical cancers are associated
with HPV infection, which is common and is acquired mainly
through sexual contact (for review see Waggoner, 2003).
There are more than one hundred known genotypes of
HPV, but only some are associated with infection of the genital
mucosa. Genital HPV types can be classified into “high-risk”
and “low-risk” varieties, based on the frequency of their identifi-
cation in cervical cancers. Low-risk types (e.g., HPV 6 and 11)
are associated with benign proliferative growths such as genital
warts. High-risk HPVs can cause cervical intraepithelial neopla-
sia (CIN) and, if left untreated, may lead to cervical cancer (for
review see zur Hausen, 2002). The majority of CIN 2-3 are
caused by HPV types 16 and 18, but several other types are
also considered high-risk. Most HPV infections are clinically
benign and are cleared naturally, but approximately 3%–10% of
women cannot clear their HPV infections. These women
become HPV carriers and are at high risk for developing cervi-
cal cancer.
This strong association between HPV and cervical cancer
applies to both squamous cell cancers and adenocarcinomas.
In addition, most cases that have initially appeared to be HPV-
negative have later been identified as false negatives. These
findings have led to the claim that HPV infection is a necessary
cause for cervical cancer, providing a strong argument for HPV
screening programs and the development of HPV vaccines.
While HPV stands out as one of the most important etiological
contributors to cervical cancer, studies have identified other fac-
tors that may play a role. These include use of oral contracep-
tives, smoking, multiple pregnancies, and coinfection with
chlamydia and/or herpes simplex virus-2 (for review see
Monsonego et al., 2004).
Screening, diagnostics, and therapeutics
Identification of cervical precancerous lesions is the primary
goal of cervical cancer screening. These precursor lesions of
cervical cancer can be classified into low-grade squamous
intraepithelial lesions (LSIL), equivalent to CIN1, and high-
grade squamous intraepithelial lesions (HSIL), equivalent to
CIN2-3. LSIL have a high percentage of spontaneous regres-
sion, whereas HSIL are more likely to develop into cervical can-
cer if left untreated. Therefore, screening methods should focus
on detecting squamous intraepithelial lesions, particularly HSIL.
However, the diagnostic reproducibility of SIL represents a sub-
stantial barrier to execution of robust translational studies of
precursor lesions of cervix. The most widely used screening
approach to detect HSIL is conventional cervical cytology, usu-
ally via Pap smear, followed by investigation of positive women
with colposcopy and directed biopsy. A definitive diagnosis of
cervical cancer or its precursor lesions requires a biopsy of the
suspicious lesion. Once a tissue diagnosis of invasive carcino-
ma has been confirmed, the patient should be staged. Staging
is determined clinically at the time of primary diagnosis and is
determined mainly based on the size of the tumor in the cervix
or its extension into the pelvis. The Federation Internationale de
Gynecologie et d’Obstetrique (FIGO) defines clinical stages of
cervical cancer as stages 0, IA1, IA2, IB1, IB2, IIA, IIA, IIIA, IVA,
or IVB based on tumor size, extension of the tumor, involvement
of regional lymph nodes, and presence of distant metastases.
The treatment options for cervical cancer are based on the
outcome of clinical staging and are generally composed of
surgery, radiotherapy, chemotherapy, and/or chemoradiothera-
py. If the cervical cancer lesion is small and well defined (stages
IA1–IB1), surgery and/or radiotherapy are probably sufficient to
control the cancer, and the five-year survival rate is very good.
For patients with larger tumors and significant vaginal involve-
ment (stages IB2–IIA), more extensive surgery and/or concomi-
tant chemotherapy and radiotherapy (chemoradiotherapy) are
necessary to provide a reasonable chance for five-year survival.
However, if tumors extend beyond the cervix (stages IIB–IVA),
chemoradiotherapy should be considered, as several random-
ized clinical trials have shown significant improvement in time to
progression and survival for patients given chemoradiotherapy
compared to radiotherapy or chemotherapy alone (Morris et al.,
1999; Whitney et al., 1999). For patients with advanced cervical
cancer (stage IVB, recurrent or refractory disease), palliative
chemotherapy and/or chemoradiotherapy may provide some
chance for five-year survival (for review, see Waggoner, 2003).
Disease mechanism and molecular targets
Numerous studies have indicated that HPV infection is neces-
sary for the development of cervical cancer. It is therefore
important to understand the biology of HPV infection in order to
describe the molecular pathogenesis of cervical cancer. HPV
initially infects basal cells of mucosal or epidermal epithelium.
All HPV types have a circular, double-stranded DNA genome
containing about 8,000 base pairs and encoding two classes of
proteins: “early” proteins, which regulate viral DNA replication
(E1, E2), RNA transcription (E2), and cell transformation (E5,
E6, E7); and “late” proteins (L1, L2), the structural components
of the viral capsid. The expression of these proteins is tightly
regulated and coupled with the differentiation status of the
infected squamous epithelial cells. As differentiating cells move
toward the more superficial cell layers, virus assembly takes
place. The viral DNA ordinarily replicates extrachromosomally.
In HPV-associated malignant transformation, viral DNA may be
integrated into the cellular DNA, and integration often results in
deletion of large sectors of the viral genome. Late genes (L1
and L2) and some early genes (such as E2 and E5) are usually
lost, leaving E6 and E7 as the principal open reading frames
found in carcinomas (for review, see zur Hausen, 2002).
Among the early genes, E6 and E7 are the two most
renowned, oncogenic proteins, since they are consistently
expressed by HPV-associated malignancies and are responsi-
ble for stimulation of proliferation. Evidence has shown that they
can immortalize cells efficiently when expressed in concert dur-
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ing natural HPV infection. This is supported by data showing
that inhibition of E6 and E7 expression can block the malignant
phenotype of cervical cancer cells. Expression of E6 leads to
unregulated cell growth by enhancing degradation of the tumor
suppressor p53 and proapoptotic BAK. E6 expression has also
been shown to contribute to stimulation of growth through acti-
vation of telomerase and inhibition of degradation of SRC fami-
ly kinases. E7 expression leads to degradation of pRb, resulting
in upregulation of p16INK4A, a cell cycle regulatory gene. Figure 2
shows HPV-infected malignant cells displaying upregulated
p16INK4A. Furthermore, E7 stimulates the S phase genes cyclin
A and cyclin E and appears to block the function of cyclin-
dependent kinase inhibitors KIP1 (p27) and WAF1 (CIP1 or
p21).These functions of E7 further break down regulation of cell
growth. E7 has also been shown to induce aneuploidy in E7-
expressing cells, which contributes to tumorigenesis. E6 and
E7, capable of inducing cellular immortalization individually,
function more efficiently when simultaneously expressed. E7 is
able to counteract p16INK4A inhibition of E6, and E6 prevents E7-
triggered apoptosis. Thus, coexpression of E6 and E7 signifi-
cantly increases transforming activity (for review see zur
Hausen, 2002).
Because E6 and E7 are vital for oncogenesis and are con-
stantly expressed in most HPV-associated cervical cancers,
they represent ideal molecular targets for development of
strategies to intervene in the progression and treatment of cer-
vical cancer, including therapeutic vaccine development. There
may be other molecular targets, however, that are important for
development of effective intervention strategies. Most HPV
infections regress spontaneously, and the reasons for progres-
sion or regression of lesions remain unclear at this point.
Identification of mechanisms determining progression or
regression of lesions will not only provide us with a better under-
standing of this disease but also provide potential molecular tar-
gets for intervention.
Animal models
There are several HPV-16 E6/E7 transgenic mouse models cur-
rently available (Arbeit et al., 1996; Lambert et al., 1993). For
example, Elson et al. have reported that using a low dose of
estrogen in E6/E7-transgenic mice led to carcinogenesis in the
transformation zone of cervix, resembling carcinogenesis of
cervical cancer as observed in humans (Elson et al., 2000).
These transgenic mice could serve as a valuable preclinical
model for preventive and therapeutic intervention aimed at
these potential molecular targets.
Recent advances in screening and HPV vaccine
development
Although the Pap smear is an important procedure historically
and has had an enormous impact on the incidence of cervical
cancer, studies suggest that the sensitivity of the Pap smear is
low (50% to 60%) and that the procedure has a high propensity
for error (Fahey et al., 1995). Two cervical screening methods
have recently been developed that may compensate for this
lack of sensitivity. One of these is liquid-based cytology, also
known as a thin-layer preparation. Recent reviews have con-
cluded that liquid-based cytology is more cost-effective and
more sensitive than conventional smear-based cytology and
that it should therefore be adopted for cervical cancer screening
(for review, see Monsonego et al., 2004). Another alternative to
the Pap smear is HPV testing. Recent studies have demonstrat-
ed HPV testing to be more sensitive than cytology alone and
that the combination of cytology and HPV testing results in a
negative predictive value of >99% (Petry et al., 2003; Sherman
et al., 2003). As a result, HPV testing has recently been
approved for use in some clinical settings in the United States.
HPV testing may one day supplant cytology as the primary
screening method for cervical cancer and its precursor lesions.
Since HPV infection precedes and plays an essential role in
the development of cervical cancer, vaccines targeting HPV-
encoded proteins may serve as feasible approaches to control-
ling cervical cancer (for review see Frazer, 2004; Roden and
Wu, 2003). There are two approaches to HPV vaccine develop-
ment. The first seeks to prevent the virus from establishing
infection in the epithelium, mainly through the induction of neu-
tralizing antibodies against viral capsid proteins. A prophylactic
vaccine should effect the complete neutralization of free virus
upon exposure before infection can occur. However, this may be
of lesser benefit to individuals who have an established infec-
tion and HPV-associated lesions. The second approach to vac-
cine development addresses the needs of these patients by
attempting to induce a cellular immune response, which may be
able to prevent neoplastic lesions and induce their regression.
This is antigen-specific immunotherapy, in which effector cells,
particularly T cells, are primed against HPV antigens expressed
by the neoplastic cells (tumor-specific antigens), such as E6
and E7. Finally, prophylaxis and therapy can be combined into
one vaccine, in an attempt to provide total coverage for people
newly exposed to high-risk virus and for people with current
infections and HPV-associated lesions. Preventive vaccines
currently in phase II/III trials include subunit vaccines composed
of HPV virus-like particles (VLPs) generated by self-assembling
of the major capsid protein L1.These trials reveal highly encour-
aging data without severe side effects (Harro et al., 2001). High
titers of type-specific neutralizing antibody were observed in
vaccinated individuals. More importantly, the trials suggest that
a VLP vaccine can prevent establishment of HPV infection and
therefore has the potential to prevent cervical cancer (Koutsky
et al., 2002). HPV therapeutic vaccine trials have shown that E6
and E7 proteins, and some peptides derived from these pro-
teins, are immunogenic in humans. No significant side effects
were observed in these trials, but no definitive therapeutic effi-
cacy has been observed in patients receiving the vaccines.
Future challenges
Endometrial cancer
In the future, a combination of approaches will be necessary to
further advance our knowledge of endometrial carcinoma so
that we can have a meaningful impact on women who are faced
with this diagnosis. Not only do we need to develop novel effec-
tive therapeutic approaches for women with advanced stage
disease through the model systems that are currently being cre-
ated, but the interaction of genetics and hormones needs to be
thoroughly elucidated so that we can determine who is at risk
for the development of invasive disease. Again, the mouse mod-
els will play a unique role in this undertaking. However, eventu-
ally, what is learned in the mouse models must be confirmed in
humans through the continued study of primary human tumors
and the women with this disease. It is only with the combination
of approaches that we will be able to change the incidence and
outcome of this common malignancy of women.
Cervical cancer
Significant progress has been made toward understanding of
HPV pathogenesis, innovative screening techniques, vaccine
development, and effective cervical cancer therapies. However,
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many challenges related to research into HPV pathogenesis
remain to be addressed: (1) characterization of risk factors lead-
ing to persistent HPV infection, (2) identification of biomarkers
that contribute to the risk of HPV-positive women for progres-
sion to HSIL and cervical cancer, (3) elucidation of the roles of
known and suspected environmental cofactors, (4) determina-
tion of the relevance of the different strains and variants of HPV
viral types, and (5) characterization of other important factors,
such as the immune responses against HPV infections and the
interaction between the host and virus. Regarding screening for
cervical cancer, further research should be focused on deter-
mining how new cervical screening technologies (such as HPV
testing and liquid based cytology) compare to conventional
screening systems for reducing cervical cancer incidence and
mortality in multiple international settings. In terms of HPV vac-
cine development, more extensive prophylactic vaccine (such
as VLPs) trials are necessary to confirm efficacy, duration of
protection, and the possibility of crossprotection. Furthermore,
therapeutic HPV vaccines should be tested in randomized
placebo-controlled clinical trials to demonstrate therapeutic effi-
cacy. Increased understanding of these issues could lead to
better management of cervical cancer through control of HPV
infection and HPV-associated lesions.
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